Combined treatment with immunoadsorption and rituximab leads to fast and prolonged clinical remission in difficult-to-treat pemphigus vulgaris

British Journal of Dermatology

Volumn 166, Issue 4, 2012, Pages 844-852

  Behzad, M ^a   Mobs C ^a   Kneisel, A ^a   Moller M ^a   Hoyer, J ^a   Hertl, M ^a   Eming, R ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; AZATHIOPRINE; DESMOGLEIN 1; DESMOGLEIN 3; IMMUNOGLOBULIN; IMMUNOGLOBULIN G ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RITUXIMAB;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DISEASE ACTIVITY; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; IMMUNOADSORPTION; LONG TERM CARE; MALE; PEMPHIGUS VULGARIS; PRIORITY JOURNAL; RELAPSE; REMISSION; RETROSPECTIVE STUDY; TREATMENT RESPONSE;

ADULT; AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; AUTOANTIBODIES; CHRONIC DISEASE; COMBINED MODALITY THERAPY; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOLOGIC FACTORS; IMMUNOSORBENT TECHNIQUES; MALE; MIDDLE AGED; PEMPHIGUS; PREDNISOLONE; REMISSION INDUCTION; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84859118066     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2011.10732.x     Document Type: Article

References (42)

1. Amagai M, Klaus-Kovtun V, Stanley JR,. Autoantibodies against a novel epithelial cadherin in pemphigus vulgaris, a disease of cell adhesion. Cell 1991; 67: 869-77.
2. Karpati S, Amagai M, Prussick R, et al. Pemphigus vulgaris antigen, a desmoglein type of cadherin, is localized within keratinocyte desmosomes. J Cell Biol 1993; 122: 409-15.
3. Amagai M, Hashimoto T, Shimizu N, et al. Absorption of pathogenic autoantibodies by the extracellular domain of pemphigus vulgaris antigen (Dsg3) produced by baculovirus. J Clin Invest 1994; 94: 59-67.
4. Hertl M,. Humoral and cellular autoimmunity in autoimmune bullous skin disorders. Int Arch Allergy Immunol 2000; 122: 91-100.
5. Amagai M, Komai A, Hashimoto T, et al. Usefulness of enzyme-linked immunosorbent assay using recombinant desmogleins 1 and 3 for serodiagnosis of pemphigus. Br J Dermatol 1999; 140: 351-7.
6. Bystryn JC, Rudolph JL,. Pemphigus. Lancet 2005; 366: 61-73.
7. Nousari HC, Anhalt GJ,. Pemphigus and bullous pemphigoid. Lancet 1999; 354: 667-72.
8. Beissert S, Werfel T, Frieling U, et al. A comparison of oral methylprednisolone plus azathioprine or mycophenolate mofetil for the treatment of pemphigus. Arch Dermatol 2006; 142: 1447-54.
9. Chams-Davatchi C, Esmaili N, Daneshpazhooh M, et al. Randomized controlled open-label trial of four treatment regimens for pemphigus vulgaris. J Am Acad Dermatol 2007; 57: 622-8.
10. Daniel BS, Murrell DF,. The actual management of pemphigus. G Ital Dermatol Venereol 2010; 145: 689-702.
11. Martin LK, Werth VP, Villaneuva EV, Murrell DF,. A systematic review of randomized controlled trials for pemphigus vulgaris and pemphigus foliaceus. J Am Acad Dermatol 2011; 64: 903-8.
12. Martin LK, Werth V, Villanueva E, et al. Interventions for pemphigus vulgaris and pemphigus foliaceus. Cochrane Database Syst Rev 2009; 1: CD006263.
13. Bhol K, Mohimen A, Ahmed AR,. Correlation of subclasses of IgG with disease activity in pemphigus vulgaris. Dermatology 1994; 189 (Suppl. 1): 85-9.
14. Amagai M, Karpati S, Prussick R, et al. Autoantibodies against the amino-terminal cadherin-like binding domain of pemphigus vulgaris antigen are pathogenic. J Clin Invest 1992; 90: 919-26.
15. Tsunoda K, Ota T, Aoki M, et al. Induction of pemphigus phenotype by a mouse monoclonal antibody against the amino-terminal adhesive interface of desmoglein 3. J Immunol 2003; 170: 2170-8.
16. Cheng S, Kobayashi M, Kinoshita-Kuroda K, et al. Monitoring disease activity in pemphigus with enzyme-linked immunosorbent assay using recombinant desmogleins 1 and 3. Br J Dermatol 2002; 147: 261-5.
17. Harman KE, Gratian MJ, Seed PT, et al. Diagnosis of pemphigus by ELISA: a critical evaluation of two ELISAs for the detection of antibodies to the major pemphigus antigens, desmoglein 1 and 3. Clin Exp Dermatol 2000; 25: 236-40.
18. Eming R, Hertl M,. Immunoadsorption in pemphigus. Autoimmunity 2006; 39: 609-16.
19. Schmidt E, Zillikens D,. Immunoadsorption in dermatology. Arch Dermatol Res 2010; 302: 241-53.
20. Eming R, Rech J, Barth S, et al. Prolonged clinical remission of patients with severe pemphigus upon rapid removal of desmoglein-reactive autoantibodies by immunoadsorption. Dermatology 2006; 212: 177-87.
21. Pfutze M, Eming R, Kneisel A, et al. Clinical and immunological follow-up of pemphigus patients on adjuvant treatment with immunoadsorption or rituximab. Dermatology 2009; 218: 237-45.
22. Shimanovich I, Herzog S, Schmidt E, et al. Improved protocol for treatment of pemphigus vulgaris with protein A immunoadsorption. Clin Exp Dermatol 2006; 31: 768-74.
23. Schmidt E, Klinker E, Opitz A, et al. Protein A immunoadsorption: a novel and effective adjuvant treatment of severe pemphigus. Br J Dermatol 2003; 148: 1222-9.
24. Luftl M, Stauber A, Mainka A, et al. Successful removal of pathogenic autoantibodies in pemphigus by immunoadsorption with a tryptophan-linked polyvinylalcohol adsorber. Br J Dermatol 2003; 149: 598-605.
25. Dorner T, Radbruch A, Burmester GR,. B-cell-directed therapies for autoimmune disease. Nat Rev Rheumatol 2009; 5: 433-41.
26. Arin MJ, Engert A, Krieg T, et al. Anti-CD20 monoclonal antibody (rituximab) in the treatment of pemphigus. Br J Dermatol 2005; 153: 620-5.
27. Ahmed AR, Spigelman Z, Cavacini LA, et al. Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. N Engl J Med 2006; 355: 1772-9.
28. Joly P, Mouquet H, Roujeau JC, et al. A single cycle of rituximab for the treatment of severe pemphigus. N Engl J Med 2007; 357: 545-52.
29. Eming R, Nagel A, Wolff-Franke S, et al. Rituximab exerts a dual effect in pemphigus vulgaris. J Invest Dermatol 2008; 128: 2850-8.
30. Hertl M, Eming R, Borradori L,. Rituximab (anti-CD20 monoclonal antibody)-ultimate or first choice in pemphigus? Dermatology 2007; 214: 275-7.
31. Schmidt E, Goebeler M, Zillikens D,. Rituximab in severe pemphigus. Ann N Y Acad Sci 2009; 1173: 683-91.
32. Shimanovich I, Nitschke M, Rose C, et al. Treatment of severe pemphigus with protein A immunoadsorption, rituximab and intravenous immunoglobulins. Br J Dermatol 2008; 158: 382-8.
33. Hertl M, Zillikens D, Borradori L, et al. Recommendations for the use of rituximab (anti-CD20 antibody) in the treatment of autoimmune bullous skin diseases. J Dtsch Dermatol Ges 2008; 6: 366-73.
34. Pfutze M, Niedermeier A, Hertl M, et al. Introducing a novel Autoimmune Bullous Skin Disorder Intensity Score (ABSIS) in pemphigus. Eur J Dermatol 2007; 17: 4-11.
35. Muller R, Svoboda V, Wenzel E, et al. IgG against extracellular subdomains of desmoglein 3 relates to clinical phenotype of pemphigus vulgaris. Exp Dermatol 2008; 17: 35-43.
36. Zillikens D, Derfler K, Eming R, et al. Recommendations for the use of immunoapheresis in the treatment of autoimmune bullous diseases. J Dtsch Dermatol Ges 2007; 5: 881-7.
37. Goebeler M, Herzog S, Brocker EB, et al. Rapid response of treatment-resistant pemphigus foliaceus to the anti-CD20 antibody rituximab. Br J Dermatol 2003; 149: 899-901.
38. Leuci S, Levine D, Zhang J, et al. Response in patients with pemphigus vulgaris to rituximab therapy. Basis of the biology of B cells. G Ital Dermatol Venereol 2009; 144: 379-409.
39. Buch MH, Smolen JS, Betteridge N, et al. Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis 2011; 70: 909-20.
40. Kwon EJ, Yamagami J, Nishikawa T, et al. Anti-desmoglein IgG autoantibodies in patients with pemphigus in remission. J Eur Acad Dermatol Venereol 2008; 22: 1070-5.
41. Rosenbach M, Murrell DF, Bystryn JC, et al. Reliability and convergent validity of two outcome instruments for pemphigus. J Invest Dermatol 2009; 129: 2404-10.
42. Murrell DF, Dick S, Ahmed AR, et al. Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus. J Am Acad Dermatol 2008; 58: 1043-6.